First Subject in Sickle Cell Disease Trial Receives Dose of Motixafortide by BioLineRx Sickle cell disease (SCD) is a genetic...
Azura Ophthalmics, a leading ophthalmic company, recently announced positive results from the Phase 2 clinical trial of their novel drug,...
JCB, IDEMIA, and Soft Space Collaborate on Phase 2 Pilot of “JCBDC” to Test Offline P2P Payments for CBDC In...
AbbVie, a global biopharmaceutical company, recently announced its acquisition of Cerevel Therapeutics, a leading neuroscience specialist. This strategic move is...
The California Institute for Regenerative Medicine (CIRM) has recently announced the allocation of $17.5 million for clinical-stage research, with a...
Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company, is intensifying its preparations for the commercial launch of resmetirom, a potential breakthrough treatment...
The Food and Drug Administration (FDA) has recently cleared the Phase 1B Investigational New Drug (IND) application for TCB-008, a...
Oxurion, a biopharmaceutical company specializing in the development of innovative treatments for retinal diseases, recently presented key findings from the...
MediciNova, a biopharmaceutical company, recently shared new findings and outcomes from their Phase 2 clinical trial of MN-166 (ibudilast) in...
CG Pharmaceuticals, a leading biopharmaceutical company, has recently announced the initiation of a Phase 2 clinical trial for the treatment...
CORSIA’s Phase 1 Updates: Approval of 6 Carbon Credit Standards The aviation industry is one of the major contributors to...
Arrowhead Pharmaceuticals, a biopharmaceutical company specializing in the development of RNA interference (RNAi) therapeutics, recently shared exciting data on two...
Phase 2 Spring Trial of LHP588, a Treatment for P. Gingivalis-positive Alzheimer’s Disease, Continues Progression Alzheimer’s disease is a devastating...
Phase 2 Spring Trial of LHP588, a Treatment for P. Gingivalis-positive Alzheimer’s Disease, Continues as Planned Alzheimer’s disease is a...
Insights from Eli Lilly’s Chief Scientist: Obesity Drug Data, Gene Editing, and a Promising Heart Drug Eli Lilly and Company,...
